PFE•benzinga•
Pfizer Announces Phase 3 TALAPRO-2 Study Results: TALZENNA + XTANDI Shows Significant OS Improvement In mCRPC Patients; 9-Month OS Gain In Unselected Paitents, 14-Month In Paitents Selected For HRR Mutations, Secondary Endpoint Met; To Be Presented at ASC
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 13, 2025 by benzinga